Table 3. CA-125 (U/ml) and RMI in the tumor groups.
| Test | Tumor group |
Tumor type | Mean±SD | Median (range) | p-value |
|---|---|---|---|---|---|
| CA-125 | Epithelial | Benign | 80±165 | 33 (4–1578) | <0.001 |
| Malignant | 510±671 | 139 (9–2034) | |||
| Benign (excluding endometriosis | 18±11 | 17 (4–50) | NA | ||
| Malignant (excluding borderline) | 680±718 | 322 (18–2034) | NA | ||
| Endometriosis | 122±205 | 61 (9–1578) | NA | ||
| Borderline lesions | 185±433 | 44 (9–1483) | |||
| Sex cord | Benign | 63±120 | 22 (9–401) | 0.093 | |
| Malignant | 13±5 | 13 (8–22) | |||
| Germ cell | Benign | 24±35 | 16 (6–324) | <0.001 | |
| Malignant | 100±130 | 49 (13–411) | |||
| Others | Benign | 40±67 | 15 (5–265) | <0.001 | |
| Malignant | 319±340 | 218 (10–1081) | |||
| All | Benign | 56±126 | 21 (4–1578) | <0.001 | |
| Malignant | 346±541 | 81 (9–2034) | |||
| Total | 105±272 | 23 (4–2034) | NA | ||
| RMI | Epithelial | Benign | 230±463 | 68 (4–3044) | <0.001 |
| Malignant | 6130±9626 | 1300 (9–31792) | |||
| Benign (excluding endometriosis) | 50±105 | 21 (4–768) | NA | ||
| Malignant (excluding borderline) | 9190±10721 | 3664 (18–31792) | NA | ||
| Endometriosis | 354±565 | 144 (9–3044) | NA | ||
| Borderline lesions | 287±426 | 137 (9–1483) | NA | ||
| Sex cord | Benign | 294±476 | 124 (9–1604) | 0.093 | |
| Malignant | 41±29 | 40 (10–88) | |||
| Germ cell | Benign | 73±167 | 27 (6–1296) | <0.001 | |
| Malignant | 289±446 | 126 (19–1644) | |||
| Others | Benign | 109±214 | 28 (9–1024) | <0.001 | |
| Malignant | 2567±3815 | 872 (40–12160) | |||
| All | Benign | 164±368 | 44 (4–3044) | <0.001 | |
| Malignant | 3739±7575 | 304 (9–31792) | |||
| Total | 768±3388 | 56 (4–31792) | NA |
CA-125: cancer antigen 125; RMI: risk of malignancy index; SD: standard deviation; NA: non-applicable